SeqLL Past Earnings Performance
Past criteria checks 0/6
SeqLL's earnings have been declining at an average annual rate of -18%, while the Life Sciences industry saw earnings growing at 16.4% annually. Revenues have been declining at an average rate of 50.9% per year.
Key information
-18.0%
Earnings growth rate
10.8%
EPS growth rate
| Life Sciences Industry Growth | 21.5% |
| Revenue growth rate | -50.9% |
| Return on equity | -926.0% |
| Net Margin | n/a |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How SeqLL makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 0 | -6 | 3 | 2 |
| 30 Sep 23 | 0 | -6 | 3 | 2 |
| 30 Jun 23 | 0 | -5 | 3 | 2 |
| 31 Mar 23 | 0 | -5 | 3 | 2 |
| 31 Dec 22 | 0 | -4 | 3 | 2 |
| 30 Sep 22 | 0 | -4 | 3 | 2 |
| 30 Jun 22 | 0 | -4 | 3 | 1 |
| 31 Mar 22 | 0 | -3 | 2 | 1 |
| 31 Dec 21 | 0 | -4 | 2 | 1 |
| 30 Sep 21 | 0 | -2 | 1 | 0 |
| 30 Jun 21 | 0 | -2 | 1 | 0 |
| 31 Mar 21 | 0 | -2 | 1 | 0 |
| 31 Dec 20 | 0 | -1 | 1 | 0 |
| 30 Jun 20 | 0 | -2 | 1 | 1 |
| 31 Mar 20 | 1 | -2 | 1 | 1 |
| 31 Dec 19 | 1 | -2 | 1 | 1 |
| 30 Jun 19 | 1 | -3 | 2 | 1 |
| 31 Mar 19 | 1 | -3 | 2 | 1 |
| 31 Dec 18 | 1 | -3 | 2 | 1 |
| 30 Sep 18 | 1 | -3 | 1 | 1 |
| 31 Dec 17 | 1 | -2 | 1 | 1 |
| 31 Dec 16 | 1 | -1 | 1 | 1 |
Quality Earnings: SEQL is currently unprofitable.
Growing Profit Margin: SEQL is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: SEQL is unprofitable, and losses have increased over the past 5 years at a rate of 18% per year.
Accelerating Growth: Unable to compare SEQL's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: SEQL is unprofitable, making it difficult to compare its past year earnings growth to the Life Sciences industry (-6.6%).
Return on Equity
High ROE: SEQL has a negative Return on Equity (-925.98%), as it is currently unprofitable.